{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:41:33Z","timestamp":1790804493746,"version":"4.1.0"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"Early diagnosis of the pathological cause, if any, of short stature in children can lead to prompt intervention with recombinant growth hormone (rGH) treatment, potentially allowing them to achieve their true genetic height potential. However, it is crucial to identify children most likely to benefit from rGH treatment.<\/jats:p>Methods<\/jats:title>This cross-sectional, retrospective study provides a broad overview of rGH prescribing patterns and evaluates both short- and long-term treatment outcomes in children treated at the Pediatric Endocrinology Clinic, Sheikh Khalifa Medical City, Abu Dhabi, UAE, between January 2011 and December 2022. One- and three-year outcome data for children treated with rGH for different diagnoses of short stature were assessed.<\/jats:p><\/jats:sec>Results<\/jats:title>Idiopathic short stature (ISS) accounted for 34.8% of the cases for which rGH was prescribed. A significant response [mean height gain of \u22650.3 standard deviation score (SDS)\/year] was seen across all assessed short-stature diagnoses, with the highest gain seen in the growth hormone deficiency (GHD) diagnosis group at the 1-year and 3-year treatment time points. More than 90% of the children diagnosed with GHD and ISS achieved normal final adult height. Younger age at rGH initiation, lower height SDS at baseline, and pre-pubertal status were associated with better outcomes post 1 and 3 years of rGH therapy. Greater response at 1 year of rGH therapy was associated with better final adult height outcome.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>ISS was the most common indication for which rGH was prescribed in this study. A favorable increment in the height SDS of the rGH-treated children during their 1- and 3-year follow-ups was observed. Age, pubertal status, baseline height SDS, and rGH response at 1 year were directly associated with significantly improved short- and long-term response to rGH treatment. These findings provide a broad overview of the baseline and therapeutic response characteristics of rGH-treated children with short stature in the UAE and can help in optimizing and personalizing treatment strategies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2025.1516967","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T10:10:37Z","timestamp":1747735837000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Recombinant growth hormone therapy in children with short stature in Abu Dhabi: a cross-sectional study of indications and treatment outcomes"],"prefix":"10.3389","volume":"13","author":[{"given":"Sara Salem","family":"Al Jneibi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Hammouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahraa","family":"Allami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Aljubeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sareea","family":"Al Remeithi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"B1","volume-title":"Short Stature","author":"Rani","year":"2023"},{"key":"B2","first-page":"43","article-title":"Evaluation of short and tall stature in children","volume":"92","author":"Barstow","year":"2015","journal-title":"Am Fam Physician"},{"key":"B3","doi-asserted-by":"publisher","first-page":"711979","DOI":"10.3389\/fped.2021.711979","article-title":"Real-world treatment patterns and outcomes of growth hormone treatment among children in Israel over the past decade (2004\u20132015)","volume":"9","author":"Ben-Ari","year":"2021","journal-title":"Front Pediatr"},{"key":"B4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2147\/DDDT.S23140","article-title":"Emerging options in growth hormone therapy: an update","volume":"5","author":"Kemp","year":"2011","journal-title":"Drug Des Devel Ther"},{"key":"B5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijpam.2016.07.002","article-title":"Diagnosis and management of growth disorders in gulf cooperation council (GCC) countries: current procedures and key recommendations for best practice","volume":"3","author":"Al Herbish","year":"2016","journal-title":"Int J Pediatr Adolesc Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1159\/000502901","article-title":"The challenge of defining and investigating the causes of idiopathic short stature and finding an effective therapy","volume":"92","author":"Inzaghi","year":"2019","journal-title":"Horm Res Paediatr"},{"key":"B7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12902-015-0073-7","article-title":"Recombinant growth hormone therapy in children with short stature in Kuwait: a cross-sectional study of use and treatment outcomes","volume":"15","author":"Al-Abdulrazzaq","year":"2015","journal-title":"BMC Endocr Disord"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1210\/jc.2009-1471","article-title":"Observed and predicted growth responses in pre-pubertal children with growth disorders: guidance of growth hormone treatment by empirical variables","volume":"95","author":"Ranke","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1210\/jc.2019-00775","article-title":"Treatment of children with GH in the United States and Europe: long-term follow-up from NordiNet\u00ae IOS and ANSWER program","volume":"104","author":"S\u00e4vendahl","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1365-2265.2012.04420.x","article-title":"Identification and management of poor response to growth-promoting therapy in children with short stature","volume":"77","author":"Bang","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1159\/000098707","article-title":"Age at growth hormone therapy start and first-year responsiveness to growth hormone are Major determinants of height outcome in idiopathic short stature","volume":"68","author":"Ranke","year":"2007","journal-title":"Horm Res Paediatr"},{"key":"B12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.4274\/jcrpe.galenos.2019.2019.0088","article-title":"Achieving optimal short- and long-term responses to paediatric growth hormone therapy","volume":"11","author":"Wit","year":"2019","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0430","article-title":"Clinical practice guidelines for the care of girls and women with turner syndrome: proceedings from the 2016 cincinnati international turner syndrome meeting","volume":"177","author":"Gravholt","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1210\/endrev\/bnad002","article-title":"International consensus guideline on small for gestational age: etiology and management from infancy to early adulthood","volume":"44","author":"Hokken-Koelega","year":"2023","journal-title":"Endocr Rev"},{"key":"B15","doi-asserted-by":"publisher","first-page":"988614","DOI":"10.3389\/fped.2022.988614","article-title":"Assessment and referral of patients with short stature by primary care physicians in the Arabian gulf region: current perspectives from a regional survey","volume":"10","author":"Kaplan","year":"2022","journal-title":"Front Pediatr"},{"key":"B16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11154-020-09590-5","article-title":"The continuum between GH deficiency and GH insensitivity in children","volume":"22","author":"Savage","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"key":"B17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1687-9856-2011-6","article-title":"Identification of factors associated with good response to growth hormone therapy in children with short stature: results from the ANSWER program\u00ae","volume":"2011","author":"Lee","year":"2011","journal-title":"Int J Pediatr Endocrinol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1516967\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T10:10:38Z","timestamp":1747735838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1516967\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":17,"alternative-id":["10.3389\/fped.2025.1516967"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1516967","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"article-number":"1516967"}}